Medicinal composition for preventing re-metastasis of primary tumor after excision

A primary tumor, surgical resection technique, applied in the field of tumor re-metastasis

Inactive Publication Date: 2017-02-22
贾力
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Surgical resection is the preferred treatment option for primary tumors, which do not require "anticancer drugs"; when drugs are needed to prevent metastatic spread of tumors after surgery, there are currently no such drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0027] Tablet preparation of combination medicine: active ingredients containing oleanane-type ginsenoside Rg3 (100mg), periostin (10mg), metapristone (2mg), aspirin (25mg), and lysine (10mg) Mixed with microcrystalline cellulose (100 mg), and modified corn starch (100 mg), and granulated and sieved. The sieved granules were mixed with modified corn starch (100 mg) and magnesium stearate (1 mg), and the mixture was compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a combination medicine capable of comprehensively preventing re-metastasis of primary tumor after excision. The combination medicine comprises five types of medicines. The medicines include medicines capable of improving intrinsic tumor immunity functions of organisms, medicines capable of inhibiting the activity of circulating tumor cells in bone marrow, medicines capable of inhibiting circulating tumor cells in blood from being adhered and implanted in endangium, medicines capable of preventing the circulating tumor cells in the blood from being aggregated in blood vessels and medicines capable of reinforcing the structures of tissue matrixes. Different tumor metastasis sites are respectively controlled by each type of medicines. The combination medicine has the advantages that the five types of medicines are optimally combined with one another, and accordingly re-metastasis of the circulating tumor cells in the blood can be effectively and safely prevented after tumor surgery.

Description

technical field [0001] The present invention relates to an optimized combination of five types of drugs, so as to comprehensively and safely prevent or adjuvantly treat tumor re-metastasis (or recurrence) in mammalian patients after surgical resection of the primary tumor. Background technique [0002] The defect of existing technology and the beneficial effect of the present invention: over the past 50 years, the death rate of other major diseases (heart disease etc.) has declined substantially (> 60%), but the cancer death rate has only reduced about 5%, wherein most Most died of tumor metastasis. The death caused by tumor metastasis is currently a global economic, social, and technological problem that needs to be solved urgently. The research and development of traditional mainstream "anticancer drugs" followed a slow and stupid route of "fighting cancer after cancer metastasis", with little effect. The current "effective" chemotherapy drugs can not effectively cont...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K38/17A61K36/75A61P35/04A61K31/167A61K31/198A61K31/415A61K31/405A61K31/567A61K36/21A61K36/074A61K33/42A61K31/663A61K31/40A61K31/616A61K31/704
CPCA61K9/2059A61K31/167A61K31/198A61K31/40A61K31/405A61K31/415A61K31/567A61K31/616A61K31/663A61K31/704A61K33/42A61K36/074A61K36/21A61K36/75A61K38/17A61K45/06A61K2300/00
Inventor 贾力
Owner 贾力
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products